IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) just announced the submission of its New Drug Application (NDA) for Rexista, it’s bioequivalent OxyContin product. The application comes a little later than first expected, but it’s now in the bag, and the result could be a game changer for the company. It’s targeting an abuse deterrent approval, and if the agency gives the asset a thumbs up for approval, and couples the approval with an abuse deterrent label, it could attract significant investor attention to IntelliPharmaCeutics. There’s also a strong potential catalyst on a commercialization partner announcement for the drug, meaning at its current valuation of $96 million (and taking into consideration a somewhat muted response to the latest NDA filing, there looks to be some degree of potential for a discount entry.
The FDA is now set to make a decision on Valeant Pharmaceuticals (NYSE:VRX)'s psoriasis drug, Brodalumab, on February 16, 2017. The Market Exclusive Intelligence Team set its sights on uncovering the truth about the delay. If you are invested in the stock, or are trading the event, you won't want to miss what we found.
|
